Aug 19, 2024, 14:45
New Insights into Stage III NSCLC Treatment from Narjust Florez
Florez Lab shared on X:
“In 2018, the PACIFIC trial revolutionized stage III NSCLC treatment with durvalumab after CRT, improving survival. But research stalled until now.
Dr. Narjust Florez’s latest publication brings new insights into this critical area.
Author: Narjust Florez
Source: Florez Lab/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 3, 2024, 11:53
Dec 3, 2024, 11:50
Dec 3, 2024, 11:43
Dec 3, 2024, 09:35
Dec 3, 2024, 09:23
Dec 3, 2024, 09:20